Center for Cell-Based Therapy, Regional Hemotherapy Center of the Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Internal Medicine Graduate Program, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Front Immunol. 2022 Aug 11;13:941011. doi: 10.3389/fimmu.2022.941011. eCollection 2022.
Systemic sclerosis (SSc) is a chronic autoimmune disease that includes fibrosis, diffuse vasculopathy, inflammation, and autoimmunity. Autologous hematopoietic stem cell transplantation (auto-HSCT) is considered for patients with severe and progressive SSc. In recent decades, knowledge about patient management and clinical outcomes after auto-HSCT has significantly improved. Mechanistic studies have contributed to increasing the comprehension of how profound and long-lasting are the modifications to the immune system induced by transplantation. This review revisits the immune monitoring studies after auto-HSCT for SSc patients and how they relate to clinical outcomes. This understanding is essential to further improve clinical applications of auto-HSCT and enhance patient outcomes.
系统性硬化症（SSc）是一种慢性自身免疫性疾病，包括纤维化、弥漫性血管病变、炎症和自身免疫。对于严重和进行性 SSc 患者，可考虑自体造血干细胞移植（auto-HSCT）。在最近几十年中，关于患者管理和 auto-HSCT 后临床结果的知识有了显著提高。机制研究有助于增加对移植引起的免疫系统改变的深度和持久性的理解。这篇综述回顾了 SSc 患者 auto-HSCT 后的免疫监测研究，以及它们与临床结果的关系。这种理解对于进一步改善 auto-HSCT 的临床应用和提高患者的预后至关重要。
